Sarit Polsky MD MPH

Dr. Polsky joined the staff at the Barbara Davis Center for Diabetes in 2014. Her early research focused on risk factors for type 2 diabetes and the management of overweight and obesity, including management with bariatric surgery. Since Dr. Polsky’s Internal Medicine residency training in the Women’s Health track, she maintained a clinical and research interest in women’s health. Dr. Polsky directs the Pregnancy and Women’s Health Clinic at the Barbara Davis Center. Dr. Polsky is the co-Director of the EPIC (Empowering Patients for Individualized Care) Conference for people living with diabetes and their supporters.

Main Research Interests:

1. Women’s Health: Dr. Polsky is interested in how diabetes affects women during the reproductive years, menopause, and post-menopausal stages. She performs studies examining how advanced diabetes technologies, like continuous glucose monitors and hybrid closed-loop insulin delivery systems, affect women during pregnancy. As certain complications of pregnancy can affect cardiac health in the long-term, she has also performed studies examining persistent cardiovascular risk factors in women after delivery.

    

2. Advanced Diabetes Technologies: Dr. Polsky has been involved in multicenter studies examining new diabetes technologies, particularly hybrid closed-loop systems. She is a site PI in the T1D Exchange QI (Quality Improvement) Collaborative, which uses data from 21 centers to track health data, diabetes device use, and other metrics across the U.S. in individuals with type 1 diabetes. Additionally, she has collaborated with other diabetes centers to assess the perceived benefits and challenges to implementing advanced diabetes technologies into the care of older adults with type 1 diabetes.

    

3. Dr. Polsky also has an interest in medications that may be used in the management of type 1 diabetes, such as new insulins and medications to reduce diabetes complications. Dr. Polsky was the site PI in the PERL Study (Preventing Early Renal Loss in Diabetes), an international, NIH-sponsored, multi-site randomized controlled trial investigating a new way to help prevent/decrease the progression of kidney problems in individuals with T1D.